Inloggad som:
QuANTUM wild AC220-168
Är du som patient intresserad av mer information om en studie, kontakta din behandlande läkare.
QuANTUM wild AC220-168
En dubbelblind, randomiserad placebokontrollerad fas 3-prövning av quizartinib, administrerat i kombination med kemoterapeutisk induktionsbehandling och konsoliderande kemoterapi samt administrerat som underhållsbehandling hos vuxna patienter med nyligen diagnostiserad FLT3-ITDnegativ akut myeloisk leukemi (QuANTUM-Wild)
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY AND ADMINISTERED AS MAINTENANCE THERAPY IN ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD NEGATIVE ACUTE MYELOID LEUKEMIA (QUANTUM-WILD)
PLACEHOLDER
A PHASE 3, DOUBLE-BLIND, RANDOMIZED,
PLACEBO-CONTROLLED TRIAL OF QUIZARTINIB
ADMINISTERED IN COMBINATION WITH
INDUCTION AND CONSOLIDATION
CHEMOTHERAPY AND ADMINISTERED AS
MAINTENANCE THERAPY IN ADULT PATIENTS
WITH NEWLY DIAGNOSED FLT3-ITD NEGATIVE
ACUTE MYELOID LEUKEMIA
(QUANTUM-WILD)
Mer information om studien för vårdgivare
1. Must be competent and able to comprehend, sign, and date an Ethics Committee (EC)- or Institutional
Review Board (IRB)-approved Informed Consent Form (ICF) before performance of any trial-specific
procedures or tests.
För fler kriterier, se publik databas-länk
Diagnosis of acute promyelocytic leukemia (APL), French-American-British classification M3 or WHO
classification of APL with translocation, t(15;17)(q22;q12), or BCR-ABL positive leukemia (ie, chronic
myelogenous leukemia in blast crisis); participants who undergo diagnostic (se länk för mer info)
Behandling
Fas 3
Kurativ
Företag
Studien ändrades senast av: Mirella Wahl (2025-04-17)